Emerging therapies in advanced hepatocellular carcinoma

ConclusionAdvanced HCC patients are difficult to treat with poor outcomes. After initial approval of sorafenib in 2007, we recently have multiple new agents that showed benefit and promising activity, and are set to change the landscape of HCC treatment.
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research